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Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopa-
thy linked to a deficiency in the metalloprotease ADAMTS13. In the current study, a novel
mouse model for acquired TTP was generated to facilitate development and validation of
new therapies for this disease. Therefore, a large panel (n = 19) of novel anti-mouse
ADAMTS13 (mADAMTS13) monoclonal antibodies (mAbs) of mouse origin was generated.
Inhibitory anti-mADAMTS13 mAbs were identified using the FRETS-VWF73 assay. Four
mAbs strongly inhibited mADAMTS13 activity in vitro (*68–90% inhibition). Injecting a
combination of 2 inhibitory mAbs (13B4 and 14H7, 1.25 mg/kg each) in Adamts13+/+mice
resulted in full inhibition of plasma ADAMTS13 activity (96 ± 4% inhibition, day 1 post injec-
tion), leading to the appearance of ultra-large von Willebrand factor (UL-VWF) multimers.
Interestingly, the inhibitory anti-mADAMTS13 mAbs 13B4 and 14H7 were ideally suited to
induce long-term ADAMTS13 deficiency in Adamts13+/+mice. A single bolus injection
resulted in full ex vivo inhibition for more than 7 days. As expected, the mice with the
acquired ADAMTS13 deficiency did not spontaneously develop TTP, despite the accumula-
tion of UL-VWFmultimers. In line with the Adamts13-/- mice, TTP-like symptoms could only
be induced when an additional trigger (rVWF) was administered. On the other hand, the
availability of our panel of anti-mADAMTS13 mAbs allowed us to further develop a sensitive
ELISA to detect ADAMTS13 in mouse plasma. In conclusion, a novel acquired TTP mouse
model was generated through the development of inhibitory anti-mADAMTS13 mAbs. Con-
sequently, this model provides new opportunities for the development and validation of
novel treatments for patients with TTP. In addition, these newly developed inhibitory anti-
mADAMTS13 mAbs are of great value to specifically study the role of ADAMTS13 in mouse
models of thrombo-inflammatory disease.
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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder clinically diag-
nosed by the occurrence of thrombocytopenia and microangiopathic hemolytic anemia [1,2].
The pathophysiology of TTP is linked with a deficiency in the von Willebrand factor (VWF)
cleaving protease ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin
type-1 repeats, member 13) [3–5]. Under normal physiological conditions, ADAMTS13
cleaves ultra-large vonWillebrand factor (UL-VWF) multimers (which are highly reactive in
binding platelets) into smaller, quiescent multimers, thereby preventing spontaneous VWF-
rich thrombus formation [6–8]. TTP patients suffer from organ ischemia, induced by the pres-
ence of these VWF-rich microthrombi in the capillaries and arterioles of mainly the brain,
heart and kidneys [7,9]. The majority of TTP patients (*95%) suffer from acquired TTP
caused by the presence of inhibitory and/or clearance-inducing anti-ADAMTS13 autoantibod-
ies (autoAbs) [10,11]. Fewer (<5%) TTP patients have congenital TTP or Upshaw-Schulman
Syndrome due to (a) mutation(s) in their ADAMTS13 gene [12]. Acute disease onset is often
induced by a secondary trigger like pregnancy, infection and surgery [13–16].
Suitable TTP animal models have been generated to study the pathophysiology of TTP and
to evaluate new therapies for this disease [17]. Animal models for congenital TTP have been
developed in mice [18,19] while animal models for acquired TTP have been generated in
baboons [20], rats [21] and mice [22]. Importantly, rodents with a congenital or acquired defi-
ciency in ADAMTS13 do not spontaneously develop TTP. Only when rats or mice with a con-
genital or acquired ADAMTS13 deficiency are triggered with Shiga toxin [18,22] or
recombinant VWF (rVWF) [19,20,22], TTP-like symptoms occur. In contrast, baboons with
an acquired deficiency in ADAMTS13 spontaneously develop the early symptoms of TTP
without the need for an additional trigger [20]. The different animal models for TTP have been
exceedingly important in investigating and validating new treatment therapies and in bringing
new drugs one-step closer to the clinic. The mouse model for congenital TTP [19] and the rat
model for acquired TTP [21] were valuable in demonstrating the efficacy of recombinant
ADAMTS13 as a novel therapy for both forms of the disease. The acquired TTP model in
baboons proved extremely useful in testing and validating the use of inhibitory anti-VWF Abs
as a drug to treat TTP [23,24]. Both recombinant ADAMTS13 and the inhibitory anti-VWF
nanobody caplacizumab are currently tested in clinical trials [25].
In the current study we wanted to add a mouse model for acquired TTP to our portfolio of
baboon [20] and rat [21] models of acquired TTP. The availability of a small animal model in
mice (and rats) is valuable, given the technical (amount of drugs needed, handling, housing
and breeding of the animals) and ethical issues related to the use of our large baboon animal
model. We generated a large panel (n = 19) of anti-mADAMTS13 mAbs to obtain inhibitory
anti-mADAMTS13 mAbs. Injecting the inhibitory mAbs in Adamts13+/+ mice and triggering
these mice with rVWF induced TTP-like symptoms. We took the advantage of the availability
of our unique anti-mADAMTS13 mAbs to additionally generate a sensitive ELISA to detect
plasma mADAMTS13 antigen.
Materials and Methods
Mice
ADAMTS13-deficient (Adamts13-/-) and wild type (WT, Adamts13+/+) mice were bred from
Adamts13B/CN2-/+ animals [18,26]. All animal experiments were performed according to proto-
cols approved by the Institutional Animal Care and Use Committee of the KU Leuven (Bel-
gium). This study was approved under project number P184/2014. Mice were anesthetized
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using isoflurane/O2. Blood was collected on trisodium citrate (7/1 (vol/vol) of blood/3.8%
sodium citrate) and EDTA (15/1 (vol/vol) of blood/0.5 M EDTA) via retro-orbital venipunc-
ture. Total blood cell counts were determined in EDTA anticoagulated blood using the Hema-
vet 950 (Drew Scientific, Dallas, USA). Plasma was obtained from blood collected on sodium
citrate by centrifugation at 2500xg for 6 min and stored at -80°C.
Construction, expression and purification of mADAMTS13 variants
WTmADAMTS13 and its MDTCS variant (mMDTCS) (Fig 1) were described previously
[26]. The T2-CUB2 variant (mT2-CUB2) (Fig 1) was constructed by amplifying the cDNA
encoding the sequence of mT2-CUB2 from the mADAMTS13-pcDNA6.1 plasmid using
Platinum1 Pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA). The PCR fragment was
cloned in the pSecTag/FRT/V5-His-TOPO1 expression vector and the sequence was verified
(GATC Biotech AG, Konstanz, Germany). Stable CHO Flp-In cells (Invitrogen) expressing
mT2-CUB2 were generated and selected using Hygromycin (Invivogen, San Diego, CA, USA).
WT mADAMTS13 and its variant mMDTCS were purified from conditioned medium using a
Heparin-Sepharose column (GE Healthcare, Waukesha, WI, USA) and dialysed against
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-buffered saline (HBS) solution
(50 mMHEPES, 5 mM CaCl2, 1 μMZnCl2 and 150 mMNaCl, pH 7.4), as previously described
[27]. The mT2-CUB2 variant was adsorbed on a Ni2+ Sepharose Fast Flow column (GE Health-
care). After washing (20 mMNaH2PO4, 500 mMNaCl, 30 mM imidazole, pH 7.4), bound
mT2-CUB2 was eluted with 20 mMNaH2PO4, 500 mMNaCl, pH 7.4, containing 500 mM
imidazole. Fractions were pooled, concentrated and dialysed against HBS.
Generation of anti-mADAMTS13 mouse mAbs
The anti-mADAMTS13 mouse mAbs were generated by immunizing Adamts13-/- mice with
recombinant mADAMTS13 in either filter-sterile PBS, complete or incomplete Freund’s adju-
vant (Sigma-Aldrich, St Louis, MO, USA), depending on the time point in the immunization
procedure. At day 59 (24 h after the last booster injection), the spleen of the immunized mice
was isolated and spleen cells were fused with Sp2/0 myeloma cells according to the method of
Köhler and Milstein [28] and as previously described [20,29,30]. Anti-mADAMTS13 Ab-pro-
ducing hybridoma cell lines were identified 14 days after fusion, using ELISA (see below). Posi-
tive hybridomas were subcloned to obtain monoclonal cell lines. Hybridomas were diluted on a
Fig 1. Schematic representation of the mADAMTS13 variants used in this study. The proximal (MDTCS) domains are represented in black
and include a metalloprotease (M), disintegrin-like (D), thrombospondin type-1 repeat (T1), cysteine-rich (C) and spacer (S) domain. Distal
(T2-CUB2) domains are represented in white and consist of seven thrombospondin type-1 repeats (T2 up to T8) and two CUB (Complement
component C1r/C1s, Urinary epidermal growth factor (Uegf) and Bone morphogenic protein-1) domains.
doi:10.1371/journal.pone.0160388.g001
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96-well microtiter culture plate (Greiner, Frickenhausen, Germany) at 1 cell/well. Two weeks
later, positive monoclonal hybridomas were identified. Hybridomas were grown in conditioned
medium and anti-mADAMTS13 mAbs were purified using a Protein G Sepharose 4 Fast Flow
column (GE Healthcare). The concentration of the purified mAbs was determined by measur-
ing absorbance at 280 nm. Purity was evaluated by SDS-PAGE with subsequent Instant Blue
Protein Gel staining (Westburg, Leusden, The Netherlands). Different batches of antibody
were used, where 13B4 had a concentration ranging from 0.85 to 1.33 mg/mL and 14H7 had a
concentration ranging from 0.92 to 1.20 mg/mL.
Identification of anti-mADAMTS13 mAb-producing hybridoma cell lines
Anti-mADAMTS13 mAb-producing hybridomas were identified using ELISA. In brief, puri-
fied recombinant mADAMTS13 was coated overnight at 1 U/mL (1 U/mL corresponds to the
concentration of mADAMTS13 in normal murine plasma [NMP] of Adamts13+/+ mice) on a
96-well microtiter plate. After blocking (3% milk in PBS), hybridoma supernatant was added.
Bound mAbs were detected after 1 h with horseradish peroxidase (HRP)-labeled goat anti-
mouse immunoglobulin G (IgG), Fc-specific (GAM-HRP, Sigma-Aldrich) (1/10,000 in PBS,
0.3% milk). Colorimetric development was done using o-phenylenediamine dihydrochloride
(OPD) and H2O2, and was stopped using 4 M sulfuric acid, after which the absorbance at 490
nm was determined.
Epitope mapping of the anti-mADAMTS13 mAbs
The epitope of all anti-mADAMTS13 mAbs was mapped against recombinant mMDTCS and
mT2-CUB2. Briefly, a 96-well microtiter plate was coated overnight with the respective anti-
mADAMTS13 mAb (6 μg/mL). After blocking, 15 nM of mMDTCS or mT2-CUB2 was added
for 1 h at 37°C. Binding was detected using the in-house developed polyclonal rabbit anti-
mADAMTS13 Ab (5 μg/mL) [31] and goat anti-rabbit IgG labelled with HRP (GAR-HRP,
Jackson ImmunoResearch, West Grove, PA, USA) (1/20,000 in PBS 0.3% milk). Colorimetric
development was performed as described above.
Development of a sensitive mADAMTS13 antigen detection assay
Detection of plasma and recombinant mADAMTS13 using ELISA was previously described
[31] and further optimized by changing the capturing mAb. Therefore, the anti-mADAMTS13
mAbs were coated separately overnight on a 96-well microtiter plate (5 μg/mL). After blocking,
a serial dilution of NMP of Adamts13+/+ mice (initial concentration of 0.1 U/mL) was added
for 1 h at 37°C. Detection of binding was done using the in-house developed polyclonal rabbit
anti-mADAMTS13 Ab (5 μg/mL) [31] and GAR-HRP. Colorimetric development was per-
formed as described above.
Activity of plasma mADAMTS13
Both the in vitro and ex vivo effect of the anti-mADAMTS13 mAbs on the proteolytic activity
of plasma mADAMTS13 was tested in the FRETS-VWF73 assay as previously described [31].
The in vitro effect was tested by addition of the mAbs (10 μg/mL) and 15% NMP to 2 μM of
the FRETS-VWF73 substrate solution in HBS (pH 7.4) with 1 mg/mL BSA (bovine serum albu-
min, Sigma-Aldrich). In addition, the activities of 2.5%, 5%, 10% and 15% NMP in the absence
of mAbs were tested to set-up a calibration curve. Generation of cleavage product was analysed
by measuring fluorescence intensities with the FLUOstar OPTIMA (BMG Labtech GmbH,
Offenburg, Germany) every 150 s for 75 min using excitation at 355 nm and emission at 460
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nm at 37°C. The proteolytic activity of plasma mADAMTS13 was determined by calculating
the slope of the cleavage reaction and comparing it to the calibration curve.
The ex vivo effect on the proteolytic activity of plasma mADAMTS13 of the individual
mAbs 13B4, 14H7 and 20A10 (all directed against mMDTCS), and the combined effect of
mAbs 13B4 and 14H7 was initially tested through retro-orbital injection (2.50 mg/kg for the
individual mAbs and 1.25 mg/kg for 13B4 and 14H7) in Adamts13+/+ mice (n = 4 for each con-
dition). Blood was taken 7 days before injection and 1, 3, 5, 7 and 14 days post injection. The
proteolytic activity of plasma mADAMTS13 was determined using the FRETS-VWF73 assay,
as described above.
Ab plasma levels in the treated Adamts13+/+ mice
The plasma concentration of the mAbs in the Adamts13+/+ mice treated with the respective
anti-mADAMTS13 mAb(s) was determined using the above described ELISA for the identifi-
cation of the anti-mADAMTS13 mAb-producing hybridoma cell lines, with some minor mod-
ifications. Briefly, purified recombinant mADAMTS13 was coated overnight at 1 U/mL on a
96-well microtiter plate. As a calibration curve, a constant amount of NMP (1/10) with a ½
dilution of the respective mAb (13B4 and/or 14H7 or 20A10, initial concentration of 2.5 μg/
mL) was added after blocking. Plasma samples of the injected mice (7 days before injection and
1, 3, 5, 7 and 14 days post injection) were added in a ½ dilution (1/10 dilution in the first well).
Bound mAbs were detected after 1 h with GAM-HRP. Colorimetric development was per-
formed as described above. The half-life of the mAbs was determined by fitting the calculated
plasma concentrations in function of time, using a logarithmic regression curve.
VWFmultimer analysis
The effect of injection of mAb 20A10 or the combination of mAbs 13B4 and 14H7 on the
plasma murine VWF (mVWF) multimer pattern of the treated Adamts13+/+ mice (described
above) was analysed as described [32,33]. Plasma samples of the injected mice (7 days before
injection and 1 and 3 days post injection) were loaded on 1.2% IEF agarose gels. After separa-
tion of plasma mVWF, gels were fixed on Gelbond (Westburg). Next, plasma mVWF was
detected using the anti-VWF-Ig labelled with alkaline phosphatase (AP) (Dako, Heverlee, Bel-
gium) and an AP conjugate substrate kit (Biorad, Hercules, CA, USA). Multimer densitometry
was performed using the ImageJ 1.48v software.
Mouse model for acquired TTP
Acquired deficiency of ADAMTS13 in Adamts13+/+ mice was obtained by injecting both
inhibitory anti-mADAMTS13 mAbs 13B4 and 14H7 (both 1.25 mg/kg) in 6 male and 6 female
mice (age of 8 weeks) at day -1. The non-functional anti-mMDTCS mAb 20A10 was injected
(2.50 mg/kg) in 5 male and 5 female Adamts13+/+ mice (age of 8 weeks) as negative control.
After 24 h (day 0), all mice were injected with recombinant human VWF (rVWF; 500 U/kg)
via the tail vein to trigger TTP. Blood and plasma were taken 7 days before injection and 1, 2, 4
and 14 days post injection. Subsequently, platelet counts were measured (Hemavet), lactate
dehydrogenase (LDH) activity (Gentaur [Biovision], SanJose, CA, USA) was determined and
the multimeric pattern was analysed as described above.
Statistical analysis
Slopes of the data of the FRETS-VWF73 assay were fitted through linear regression. Means
were compared with the reference, using the Student’s t-test (parametric, unpaired, 2-tailed).
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Probabilities of P< 0.05 (), P< 0.01 (), P< 0.001 () and P< 0.0001 () were taken as
significant for rejection of the null hypothesis. All statistical applications were performed using
the GraphPad Prism v5.03 software (GraphPad Software, Inc., San Diego, CA, USA).
Results
Development of anti-mADAMTS13 mAbs
We aimed at generating a large panel of anti-mADAMTS13 mAbs to obtain inhibitory
mAbs in order to develop an acquired ADAMTS13 deficiency in mice. In addition,
novel (non-inhibitory) anti-mADAMTS13 mAbs could be essential new tools to detect
mADAMTS13 antigen in murine plasma. Hence, Adamts13-/- mice were immunized with
recombinant mADAMTS13, B-cells were fused with Sp2/0 myeloma cells and hybridoma cells
expressing anti-mADAMTS13 mAbs were selected. This led to the generation of 19 anti-
mADAMTS13 mAbs. To identify anti-amino(N)-terminal (MDTCS) or anti-carboxyl(C)-ter-
minal (T2-CUB2) mAbs (Fig 1), anti-ADAMTS13 mAbs were mapped against recombinant
mMDTCS and mT2-CUB2. Six mAbs had an epitope in the MDTCS part (Fig 2A) and 13 had
an epitope in the T2-CUB2 part (Fig 2B). A schematic overview of the epitopes of all anti-
mADAMTS13 mAbs is given in Fig 2C.
Fig 2. Epitopemapping and epitope overview of the developed anti-mADAMTS13mAbs. The epitope of each anti-mADAMTS13 mAb was
mapped against both mMDTCS (A) and mT2-CUB2 (B). Individual anti-mADAMTS13 mAbs were coated, recombinant mMDTCS (A) or
mT2-CUB2 (B) were added and binding of the respective mADAMTS13 variant was detected using the polyclonal anti-mADAMTS13 rabbit IgG
and GAR-HRP. Black and white bars represent respectively anti-mMDTCS and anti-mT2-CUB2mAbs. The previously reported mAb 20A10 [31]
was used as a positive (A) and negative (B) control. (C) Epitope overview of the developed anti-mADAMTS13 mAbs. The previously developed
mAb 20A10 [31] is marked by a dark frame.
doi:10.1371/journal.pone.0160388.g002
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Generation and validation of a sensitive mADAMTS13 antigen assay
In our first attempt to generate anti-mADAMTS13 mAbs, only a single anti-mADAMTS13
mAb (mAb 20A10) was obtained [31]. With this and an in-house developed polyclonal anti-
mADAMTS13 rabbit IgG [31], we succeeded in developing the first ELISA to detect plasma
mADAMTS13. The 19 novel anti-mADAMTS13 mAbs created the opportunity to improve
the sensitivity of this unique assay. All mAbs, including 20A10, were coated and their capacity
to capture plasma mADAMTS13 was evaluated. Anti-mMDTCS mAb 14H7 and anti-
mT2-CUB2 mAb 9F2 were found most efficient in capturing plasma mADAMTS13 (Fig 3).
The efficacy of the three anti-mADAMTS13 mAbs (9F2, 14H7 and 20A10) in capturing
plasma mADAMTS13 was further evaluated by determination of the repeatability, reproduc-
ibility, detection limit (DL) and quantification limit (QL) of the three respective plasma
mADAMTS13 detection assays. The repeatability was determined by testing ten dilutions (1/5
to 1/2560) of NMP on six replicates in one run. Coefficients of variation (CV; calculated as
standard deviation divided by the mean, multiplied by 100%) ranged from 2 to 9% for 9F2, 3 to
9% for 14H7 and 3 to 7% for 20A10 (Table 1). The reproducibility was calculated by analysing
six replicates of ten dilutions (1/5 to 1/2560) of NMP in three runs by two technicians. The CV
ranged from 4 to 23% for 9F2, 4 to 16% for 14H7 and 5 to 17% for 20A10 (Table 1). The DL
(defined as 3x SD above the mean zero standard) of plasma mADAMTS13 was a dilution of 1/
640 (1.56 mU/mL), 1/1280 (0.78 mU/mL) and 1/320 (3.1 mU/mL) for 9F2, 14H7 and 20A10
respectively. The QL (defined as the minimum concentration that can be measured from assay
to assay with CV< 20%) was equal to the DL.
In conclusion, the novel panel of 19 anti-mADAMTS13 mAbs resulted in the development of a
more sensitive ADAMTS13 detection ELISA, using either the anti-mMDTCSmAb 14H7 (DL and
QL of 0.78 mU/mL) or the anti-mT2-CUB2mAb 9F2 (DL and QL of 1.56 mU/mL) as a capturing
mAb, compared to the use of the anti-mMDTCSmAb 20A10 (DL and QL of 3.1 mU/mL).
In vitro identification of inhibitory anti-mADAMTS13 mAbs
In order to obtain acquired deficiency in Adamts13+/+ mice, inhibitory anti-mADAMTS13
mAbs had to be identified. Hence, all mAbs were tested in the FRETS-VWF73 assay to evaluate
Fig 3. Development of a sensitive mADAMTS13 detection assay. (A) Binding of plasmamADAMTS13 to the anti-mADAMTS13mAbs was
tested in ELISA. The respective anti-mMDTCS (black) and anti-mT2-CUB2 (white) mAbs were coated on a 96-well microtiter plate. After blocking,
plasmamADAMTS13 was added (0.1 U/mL) and was detected using the polyclonal anti-mADAMTS13 rabbit IgG and GAR-HRP. (B) The same
ELISA was performed as in A in triplicate for anti-mT2-CUB2 mAb 9F2, anti-mMDTCSmAb 14H7 and the previously reported anti-mMDTCSmAb
20A10 [31]. Binding was calculated relative to binding of 0.10 U/mL plasmamADAMTS13 to 20A10 (which was set to a value of ‘1.0’). Error bars
represent the SD of the three independently performed experiments.
doi:10.1371/journal.pone.0160388.g003
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their inhibitory effect on the proteolytic activity of plasma mADAMTS13. Four anti-mMDTCS
mAbs strongly inhibited mADAMTS13 activity (*68–90% inhibition) while 4 anti-
mT2-CUB2 mAbs showed a weak inhibitory effect (*20% inhibition) (Fig 4A). Full inhibition
of mADAMTS13 activity (100%) was obtained by combining mAbs 13B4 and 14H7 (Fig 4B).
Ex vivo characterization of inhibitory anti-mADAMTS13 mAbs 13B4 and
14H7
We next investigated the ex vivo effect of inhibitory mAbs 13B4 and 14H7 by injecting a dose
of 2.50 mg/kg in Adamts13+/+ mice. Mice injected with the non-inhibitory mAb 20A10 (2.50
mg/kg) were used as a control. When either anti-mADAMTS13 mAb 13B4 or 14H7 was
injected in Adamts13+/+ mice, only partial inhibition of mADAMTS13 activity was observed
(at day 1, 3, 5 and 7 post injection, respectively 62 ± 3%, 47 ± 13%, 28 ± 17% and 27 ± 7% inhi-
bition for 13B4; and 74 ± 7%, 69 ± 2%, 58 ± 9% and 65 ± 4% inhibition for 14H7, Fig 5A and
Fig 4. A subset of anti-mMDTCSmAbs inhibit plasmamADAMTS13 activity. The effect of anti-mADAMTS13 mAbs on the proteolytic activity
of plasmamADAMTS13 was tested in vitro using the FRETS-VWF73 assay. (A) All anti-mADAMTS13 mAbs, both anti-mMDTCS and anti-
mT2-CUB2mAbs, were tested. For each condition, the activity of plasmamADAMTS13 was calculated using a calibration curve of 2.5%, 5%, 10%
and 15%NMP. (B) Time profile of the cleavage of the FRETS-VWF73 substrate by plasmamADAMTS13, in the absence or presence of mAbs
13B4 and/or 14H7. Error bars represent the SD of at least three independently performed experiments.
doi:10.1371/journal.pone.0160388.g004
Table 1. Validation of the mADAMTS13 detection ELISA’s.
Repeatability (CV, %) Reproducibility (CV, %)
Dilution of NMP 9F2 14H7 20A10 9F2 14H7 20A10
1/5 2 3 3 4 5 7
1/10 3 3 3 4 5 6
1/20 4 4 4 5 6 6
1/40 4 4 3 9 7 5
1/80 5 4 7 6 5 17
1/160 4 3 5 5 4 8
1/320 5 5 5 11 14 6
1/640 5 4 5 5 7 6
1/1280 6 9 6 13 16 7
1/2560 9 6 6 23 8 8
Anti-mADAMTS13 mAbs 9F2, 14H7 and 20A10 were coated, different dilutions of NMP were added and bound plasma mADAMTS13 was detected with the
polyclonal anti-mADAMTS13 rabbit IgG and GAR-HRP. The CV (%) was calculated for each dilution.
doi:10.1371/journal.pone.0160388.t001
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S1 Fig). At 14 days post injection, mADAMTS13 activity was fully recovered in mice injected
with 13B4 but not in mice injected with 14H7 (6 ± 21% and 34 ± 13% inhibition respectively,
Fig 5A and S1 Fig). Injection of the non-inhibitory mAb 20A10 did not affect mADAMTS13
activity ex vivo (Fig 5A and S1 Fig). On the other hand, administration of the combination of
13B4 and 14H7 (1.25 mg/kg each) resulted in full inhibition of mADAMTS13 ex vivo for up to
7 days (96 ± 4%, 94.7 ± 0.4%, 92 ± 1% and 91 ± 3% inhibition at day 1, 3, 5 and 7 days post
injection respectively, Fig 5A and S1 Fig). At day 14 post injection, mADAMTS13 function was
fully restored (101 ± 15% activity, Fig 5A and S1 Fig). The long-lasting inhibition of
mADAMTS13 activity coincided with the long half-life of the injected mAbs (respectively
4.7 ± 0.5 days, 4.9 ± 0.7 days, 4.1 ± 0.4 days and 4.3 ± 0.7 days for mAb 13B4, 14H7, the combi-
nation of 13B4 and 14H7 and the individual mAb 20A10, Fig 5B). In addition, mADAMTS13
antigen levels did not change upon injection of 13B4, 14H7 or 20A10 (Fig 5C) while a reduc-
tion of*70% in mADAMTS13 antigen was observed when both mAbs 13B4 and 14H7 were
injected, which was normalized 14 days post injection (Fig 5C). These data show that the
acquired deficiency of ADAMTS13 induced by injecting both mAbs 13B4 and 14H7 is the
combined result of inhibition and clearance of ADAMTS13. As expected in view of what is
observed in Adamts13-/-mice [18,34], full inhibition of mADAMTS13 function in Adamts13+/+
mice did not result in TTP as platelet counts did not change in these mice (Fig 5D). Nevertheless,
analysis of the VWFmultimer pattern (Fig 5E and 5F) revealed an increase in high molecular
weight (HMW)multimers on day 1 and day 3 post injection of both mAbs 13B4 and 14H7 com-
pared to VWFmultimers on day -7 or of mice injected with mAb 20A10, supporting the achieve-
ment of an acquired ADAMTS13 deficiency in these mice. As observed for Adamts13-/- mice,
additional triggers like recombinant hVWF [19] or Shiga toxin [18] are needed to induce TTP in
mice with an acquired ADAMTS13 deficiency.
Acquired TTP mouse model
To develop an acquired TTPmouse model, animals with an acquired deficiency in mADAMTS13
were therefore additionally triggered using rVWF [19]. Twenty-four hours after (‘day 0’) injection
of both mAb 13B4 and 14H7 (1.25 mg/kg each) or the non-inhibitory mAb 20A10 (2.50 mg/kg)
as a control (n 12, ‘day -1’), all mice were triggered with 500 U/kg rVWF. Blood and plasma
were taken 7 days before (‘day -7’) the experiment and at day 1, 2, 4 and 14. Adamts13+/+ mice
injected with both 13B4 and 14H7 and triggered with rVWF developed severe thrombocytopenia
(223 ± 101 x 103 platelets/μL compared to 723 ± 99 x 103 platelets/μL before injection of the trigger,
Fig 6A) in contrast to mice injected with the control mAb 20A10 (611 ± 99 x 103 platelets/μL com-
pared to 760 ± 168 x 103 platelets/μL before injection of the trigger, Fig 6A). Thrombocytopenia
persisted for 48 h in Adamts13+/+ mice injected with 13B4 & 14H7 (321 ± 65 x 103 platelets/μL, S2
Fig) and recovered 4 days after the injection with rVWF (S2 Fig). Two weeks after injection of
rVWF (day 14), the platelet number was restored to the normal physiological level (S2 Fig). Also
lactate dehydrogenase (LDH) activity, a marker for tissue damage present during TTP [35], was
increased in mice injected with 13B4 & 14H7 compared to mice treated with 20A10 (Fig 6B).
In conclusion, a murine model for acquired TTP was established by inhibition of
mADAMTS13 activity using inhibitory anti-mADAMTS13 mAbs and by subsequently trigger-
ing the mice with recombinant hVWF.
Discussion
In this study, we present a mouse model for acquired TTP by injecting a combination of the
two inhibitory mAbs 13B4 and 14H7, selected from our large panel (n = 19) of novel anti-
mADAMTS13 mAbs (Figs 1 and 4). A single dose injection of mAbs 13B4 and 14H7 in
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Fig 5. Characterization of the ex vivo inhibitory effect of anti-mMDTCSmAbs 13B4 and 14H7. Adamts13+/+mice (n = 4, per condition)
were injected with 2.50 mg/kg of mAb 13B4, 14H7 or 20A10 or with a combination of mAbs 13B4 and 14H7 (1.25 mg/kg each) on day 0
(black arrow). The optimal injection dose of mAb was determined in separate experiments (data not shown). Blood was retrieved 7 days
before (‘day -7’) and 1, 3, 5, 7 and 14 days post injection. (A) The influence of the different mAbs on the proteolytic activity of mADAMTS13
was determined using the FRETS-VWF73 assay. Activities were calculated based on the slope of the proteolysis reactions (S1 Fig). (B)
PlasmamAb levels (μg/mL) were determined using ELISA. Plates were coated with recombinant mADAMST13, blocked and plasma of the
respective mice was added. Bound mAbs were detected using GAM-HRP. (C) The amount of mADAMTS13 (%) in plasma was determined
using ELISA. PlasmamADAMTS13 was captured using the anti-mT2-CUB2mAb 9F2. After blocking, the respective plasma samples were
added. Finally, bound mADAMTS13 was detected using the polyclonal anti-mADAMTS13 rabbit IgG and GAR-HRP. (D) Platelet counts were
measured of the respective mice samples. Error bars represent the SD (n = 4, per condition). (E) The plasmamVWFmultimer pattern was
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Adamts13+/+ mice resulted in an acquired deficiency of plasma mADAMTS13 and an increase
in HMWVWFmultimers (Fig 5). Acquired ADAMTS13 deficiency was due to complete inhi-
bition of the proteolytic activity and partial clearance of mADAMTS13 (Fig 5). Finally, onset of
TTP (reflected by thrombocytopenia and elevated LDH activity, Fig 6) was triggered through
the tail vein injection of rVWF [19]. A mouse model for acquired TTP where ADAMTS13 defi-
ciency is the result of both inhibition and clearance of the enzyme is in line with the type of
acquired ADAMTS13 deficiency observed in humans. Indeed, besides the presence of inhibi-
tory anti-ADAMTS13 antibodies in patients’ plasma, Thomas et al. recently suggested that
ADAMTS13 clearance might be a major pathological mechanism in acquired TTP [36].
Our mouse model of acquired TTP expands our portfolio of acquired rat and baboon TTP
models [20,21]. Investing in different animal models of acquired TTP is essential since novel
treatment strategies have to be carefully evaluated in different types of animal models before
they can safely enter clinical trials. In addition, each type of animal model has its own advan-
tages and disadvantages [17]. The small rodent models of acquired TTP allow high throughput
screening of novel drugs since mice and rats are easy to handle, breed and house and only
small amounts of drugs are needed. On the other hand, due to their evolutionary distance from
humans and due to the need of additional triggers such as rVWF and Shiga toxin, translation
of data obtained in mice and rats to humans is not always evident. The novel mouse model
might be better suited to study the treatment efficacy of new drugs than the rat model as TTP
symptoms last for 48h in the mouse (Fig 6) compared to 24h in the rat [21]. This shows that
the time window to study treatment for acquired TTP is larger in mice compared to rats. The
baboon model [20] is less straightforward to use compared to the mouse and rat models
because of ethical issues, more complicated handling, breeding and housing and large amount
of drugs that are needed. Nevertheless, if novel drugs do not cross-react with mouse or rat
ADAMTS13 and/or an animal is needed that is evolutionary closely related to humans,
baboons are crucial in drug development. A limitation of all animal models of acquired TTP
determined for a new cohort of treated mice (n = 5, per condition) 7 days before (‘day -7’) and 1 and 3 days post injection of mAb(s) 20A10 or
the combination of mAbs 13B4 and 14H7). Representative multimer patterns are given. Low, middle and high molecular weight (respectively
LMW [1–5 bands], MMW [6–10 bands] and HMW [>10 bands]) multimers and UL-VWFmultimers (brace) are indicated. (F) The percentage
HMWmultimers was calculated using the ImageJ 1.48v software.
doi:10.1371/journal.pone.0160388.g005
Fig 6. Mousemodel for acquired TTP. The mAbs 20A10 (2.50 mg/kg) or 13B4 and 14H7 (1.25 mg/kg each) were retro-orbitally injected in
Adamts13+/+mice at day -1. TTP was induced by intravenous tail injection of rVWF (500 U/kg) at day 0. Blood sampling was performed 7 days
before initiating the experiment (‘day -7’) and 24 h post injection of rVWF (‘24 h PI rhVWF’). (A) Platelet counts and (B) LDH activity levels were
measured. Each dot represents the value for a single mouse (n 12).
doi:10.1371/journal.pone.0160388.g006
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however, is that injection of the inhibitory anti-ADAMTS13 antibodies does not reflect the
continuous production of anti-ADAMTS13 antibodies as in acquired TTP patients.
The long-term inhibitory properties of anti-mADAMTS13 mAbs 13B4 and 14H7 (up to
seven days with one bolus injection, Fig 5) create the possibility of inactivating ADAMTS13 in
any type of knock out (KO) mouse without the need of crossing these KO mice with
Adamts13-/- mice, which is highly time- and labour-intensive. The inhibitory mAbs 13B4 and
14H7 will additionally create great potential to determine the role of ADAMTS13 in other dis-
eases besides TTP. Indeed, ADAMTS13 seems to play a role in thromboinflammatory diseases
like atherosclerosis [37], myocardial infarction [38–41], ischemic stroke [40,42], preeclampsia
[43,44] and cerebral malaria [45].
Finally, our effort to generate mAbs also resulted in the improvement of the sensitivity of
the plasma mADAMTS13 detection assay [31]. Capturing plasma mADAMTS13 with the
anti-mMDTCS mAb 14H7 or anti-mT2-CUB2 mAb 9F2 increased the sensitivity from 3.1
mU/mL (with mAb 20A10 as coating) to respectively 0.78 mU/mL and 1.56 mU/mL. In addi-
tion to the increased sensitivity, both assays are also able to detect plasma mADAMTS13 from
mouse strains expressing the short form of mADAMTS13, which lacks the C-terminal
mT7-CUB2 domains (data not shown) [46].
In conclusion, we described a novel mouse model for acquired TTP, using the well-charac-
terized inhibitory anti-mADAMTS13 mAbs 13B4 and 14H7. In line with the rat model for
acquired TTP, this mouse model creates the opportunity to further investigate novel treatment
strategies for acquired TTP before performing large animal studies. Furthermore, these mAbs
can also be used to further study the role of ADAMTS13 in other diseases beyond TTP.
Supporting Information
S1 Fig. Ex vivo inhibition of plasma mADAMTS13 activity by mAbs 13B4 and 14H7.
Adamts13+/+ mice (n = 4, per condition) were injected with 2.50 mg/kg of mAb 13B4, 14H7 or
20A10 or with both mAbs 13B4 and 14H7 (1.25 mg/kg each). Plasma was retrieved 7 days
before (‘day -7’) and 1, 3, 5, 7 and 14 days post injection. The influence of the respective mAbs
on the proteolytic activity of mADAMTS13 was determined using the FRETS-VWF73 assay.
Slopes were calculated using linear regression and used for activity determination (Fig 5A).
Error bars represent the SD (n = 4, per condition).
(TIFF)
S2 Fig. Time course of platelet counts in the acquired TTP mouse model.Mice injected
(‘day -1’) with mAbs 20A10 (white dots) or 13B4 & 14H7 (black dots) were triggered with 500
U/kg rVWF on day 0 (grey arrow, ‘rhVWF’). Platelet counts were measured 6 days before
injection (‘day -7’) of the mAbs and after injection of rVWF. Each dot represents the value for
a single mouse (n 8).
(TIFF)
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